Ferroptosis Blockade During Machine Perfusion: A New Lever for Donation After Circulatory Death Heart Transplantation?

Donation after circulatory death (DCD) has moved from an experimental concept to a clinical reality in heart transplantation.1 Yet every DCD heart carries a history of warm ischemia/reperfusion injury (IRI). Even with modern ex vivo perfusion platforms, we are still largely “observing” these organs rather than actively reprogramming their injury response.2 The study by Pan et al3 in this issue takes an important step toward changing that paradigm by targeting ferroptosis during normothermic ex vivo heart perfusion (EVHP) Figure 1. Ferroptosis—iron-dependent lipid peroxidation leading to membrane injury and cell death—has emerged as a central pathway in IRI across organs. Liproxstatin-1 (Lip-1), a potent ferroptosis inhibitor, has shown protective effects in lung, liver, and kidney models, but its role in heart transplantation, particularly in DCD hearts, remains unexplored.4 Pan et al3 use a rat DCD model with 15 min of warm ischemia, followed by 3 h of normothermic EVHP and heterotopic transplantation, to test whether adding Lip-1 to the perfusate can improve graft performance.3 The answer, at least in this experimental setting, appears to be yes. Lip-1 supplementation improves early graft function, both during EVHP and 4 h after transplantation, and attenuates biochemical and histological hallmarks of injury: reduced markers of ferroptosis (GPX4, SLC7A11, ACSL4, COX-2), lower oxidative stress and apoptosis, diminished inflammatory cytokine expression, and better-preserved tissue architecture. Importantly, the authors also document endothelial-level protection via CD31 staining, reminding us that the vasculature is a critical target of reperfusion therapy, not just a bystander. Beyond these individual findings, the work is valuable for how it frames when and where intervention might be most effective. By incorporating temporal tissue sampling after warm ischemia, after EVHP, and posttransplant, the study delineates the dynamic profile of ferroptosis activation. The data suggest that ferroptotic signaling intensifies during ex vivo perfusion—a window in which the heart is outside the body, accessible, and hemodynamically monitored. This reinforces a key conceptual point: normothermic EVHP is more than a logistics tool; it is an interventional platform where targeted drugs can be delivered under real-time functional control.5 Where does this position the field? Clinically, DCD heart transplantation is being enabled by 2 main technological routes: normothermic machine perfusion and normothermic regional perfusion.6 Both approaches mitigate cold ischemia and allow physiological or pseudophysiological reperfusion before implantation. Yet even with these advances, primary graft dysfunction remains a concern, and the usable DCD heart pool remains underexploited.7 Pan et al3 add a mechanistic layer to this story: they support the notion that simply restoring flow is not enough—we must also modulate the regulated cell-death programs that are unleashed during ischemia and reperfusion. Will this particular intervention, Lip-1 during EVHP, directly change clinical practice in the near term? Probably not yet. The study is based on a small-animal model, with a relatively short follow-up (hours rather than days or weeks) and no data on immune responses or chronic remodeling. Lip-1 itself is not a clinically approved drug, and its safety profile in large animals and humans—especially under conditions of intense oxidative and inflammatory stress—remains undefined. However, as a proof-of-concept, the work clearly advances the field in at least 3 ways: 1. It validates ferroptosis as a druggable target in DCD hearts under realistic preservation conditions. The combination of functional and molecular readouts under EVHP and after transplantation is stronger than those from isolated cells or Langendorff models and is directly relevant to current clinical workflows. 2. It supports the strategic use of machine perfusion as a therapeutic, not merely diagnostic, platform. If ferroptosis inhibition works in this setting, other interventions—antioxidants, anti-inflammatory agents, and gene therapies—can be rationally layered on top of EVHP protocols. 3. It underscores the importance of the endothelium as an integrated part of myocardial protection. By documenting endothelial preservation, the study bridges parenchymal and vascular injury, a crucial step for translating early biochemical benefit into meaningful reductions in primary graft dysfunction. What, then, are the next steps? A logical trajectory would include the following: Large-animal validation in clinically relevant DCD models, using current perfusion platforms and clinically realistic warm ischemia times. This will test not only efficacy but also the feasibility of drug delivery, dosing, and washout. Extension of follow-up beyond the early reperfusion window to capture myocardial recovery, arrhythmia susceptibility, right ventricular performance, and interaction with standard immunosuppression. Short-term hemodynamics are encouraging but do not fully predict long-term graft survival or failure modes. Dose–response and safety profiling of ferroptosis inhibitors under EVHP conditions. Ferroptosis is part of a tightly regulated redox landscape; oversuppression may interfere with physiological signaling or immune cell function. Understanding off-target effects and optimal exposure will be essential before moving toward clinical translation. Combination strategies integrating ferroptosis blockade with other protective approaches, such as mitochondrial stabilization, anti-inflammatory modulation, or tailored perfusate composition. Given the multifactorial nature of IRI, it is unlikely that a single pathway blockade will be the “magic bullet.” Biomarker development to monitor ferroptosis activity and treatment response in real time during EVHP. Linking mechanistic markers to readily measurable perfusate or imaging parameters would greatly enhance clinical applicability. Taken together, the work by Pan et al does not close the chapter on DCD heart protection; it opens a promising new one. It reminds us that the future of heart transplantation—especially in the DCD setting—will likely be written at the crossroads of advanced preservation technology and targeted molecular therapy. As we strive to expand the donor pool without compromising outcomes, interventions that reshape the biology of the injured heart during ex vivo perfusion may become as important as the devices that keep it beating.FIGURE 1.: Ferroptosis blockade as a therapeutic lever during normothermic EVHP in DCD heart transplantation. Schematic overview of the injury cascade in DCD hearts, in which warm ischemia and subsequent reperfusion during normothermic EVHP trigger ferroptosis-mediated lipid peroxidation, oxidative stress, inflammation, endothelial damage, and primary graft dysfunction. In the rat DCD model of Pan et al,3 addition of the ferroptosis inhibitor Lip-1 to the perfusate during 3 h of EVHP attenuated ferroptosis signaling (GPX4, SLC7A11, ACSL4, COX-2), reduced oxidative and inflammatory injury, preserved endothelial integrity, and improved early posttransplant graft function, illustrating EVHP as an interventional platform for targeted molecular therapies in DCD heart transplantation. DCD, donation after circulatory death; EVHP, ex vivo heart perfusion; Lip-1, liproxstatin-1.